MDx/CDx Focus: EC Approves Kalydeco; Cabozantinib in PGx-Targeted NSCLC; Ponatinib, CDx FDA Filing
August 01, 2012
MDx/CDx Focus: EC Approves Kalydeco; Cabozantinib in PGx-Targeted NSCLC; Ponatinib, CDx FDA Filing
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- FDA Approves Ariad's Iclusig for Molecularly Defined, TKI-Resistant Leukemias
December 19, 2012 / Pharmacogenomics Reporter - MolecularMD Pulls PMA After FDA Says Companion Dx Not Needed to Establish Ponatinib Efficacy, Safety
September 19, 2012 / Pharmacogenomics Reporter - MDx/CDx Focus: FDA Accepts Pfizer's Bosutinib NDA; Kalydeco Approval; AssureRx Credit Line; and more
February 1, 2012 / Pharmacogenomics Reporter - Vertex Says CF Patients with Double F508del Mutation Showing Improvement in VX-809/Kalydeco Trial
May 23, 2012 / Pharmacogenomics Reporter - Vertex Completes NDA on CF Drug for G551D Mutation, Releases Data on Other Targeted CF Therapies
November 9, 2011 / Pharmacogenomics Reporter